Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem
Authors:
- 21 October 2008
- journal article
- pharmacogenetics
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 65 (3) , 239-247
Abstract
Objective The aim of this study was to assess the influence of the cytochrome (CYP450)3A5 and multidrug resistance (MDR1) gene polymorphisms on cyclosporine A (CsA) trough concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Methods CYP3A5*3 (A6986G) and MDR1 C1236T, G2677T/A and C3435T polymorphisms were determined by PCR followed by restriction fragment length polymorphism (RFLP) analysis. A total of 112 Chinese renal transplant patients were enrolled in the study. The whole blood trough concentration was measured at 7 days after transplantation, and the dose-adjusted trough levels were compared among the different genotypes. Results The dose-adjusted trough levels of CsA were significantly higher in MDR1 2677TT carriers than in GG plus GT carriers (59.5 ± 15.9 vs. 34.5 ± 9.4 vs. 43.2 ± 13.6 ng/mL per mg per kg; P < 0.0001). In patients who were co-treated with diltiazem, compared with carriers of haplotype T-T-C, the carriers of haplotype C-G-C and haplotype T-G-T had significantly lower dose-adjusted trough blood concentrations of CsA than the non-carrier group (P = 0.002, P = 0.000 and P = 0.000, respectively). However, no evidence was found that there was a relationship between the CYP3A5*3, MDR1 C1236T and MDR1 C3435T polymorphisms and CsA dose-adjusted trough concentrations. Conclusion This study demonstrated that the G2677T/A single nucleotide polymorphisms in MDR1 and MDR1 haplotypes C-G-C, T-G-T and T-T-C are associated with the CsA concentration during the very early post-transplant period in Chinese renal transplant patients co-treated with diltiazem. These polymorphisms may be useful for determining the appropriate initial dose of CsA after renal transplantation.Keywords
This publication has 39 references indexed in Scilit:
- Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groupsJournal of Clinical Pharmacy and Therapeutics, 2007
- MDR1 C3435T Polymorphisms Correlate With Cyclosporine Levels in De Novo Renal RecipientsTransplantation Proceedings, 2006
- EFFECTS OF GENETIC POLYMORPHISMS OFCYP3A4,CYP3A5ANDMDR1ON CYCLOSPORINE PHARMACOKINETICS AFTER RENAL TRANSPLANTATIONClinical and Experimental Pharmacology and Physiology, 2006
- CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese populationClinica Chimica Acta, 2005
- The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patientsPharmacogenetics, 2004
- MDR1 Haplotypes Do Not Affect the Steady‐State Pharmacokinetics of Cyclosporine in Renal Transplant PatientsThe Journal of Clinical Pharmacology, 2003
- Pharmacogenomics — Drug Disposition, Drug Targets, and Side EffectsNew England Journal of Medicine, 2003
- P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.Journal of Clinical Investigation, 1996
- Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipientsBritish Journal of Clinical Pharmacology, 1996
- The effect of food and bile acid administration on the relative bioavailability of cyclosporin.British Journal of Clinical Pharmacology, 1990